Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 33,180 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Completed Phase 3 Interventional Results available

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

NCT02020889
View directory record Official record
Conditions
Churg-Strauss Syndrome
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

NCT04501874
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
EMB-001, EMB-001 Placebo
Drug
Lead sponsor
Embera NeuroTherapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
San Diego, California • Miami, Florida • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 13, 2026, 2:27 AM EST
Terminated Phase 4 Interventional Results available

Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)

NCT04738318
View directory record Official record
Conditions
Elbow Fracture
Interventions
Glucocorticoids, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Nov 13, 2026, 2:27 AM EST
Recruiting Phase 2 Interventional

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

NCT06812390
View directory record Official record
Conditions
Cirrhosis, Ascites Hepatic
Interventions
Albumin infusion (25% albumin), Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Anahita Rabiee MD MHS
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Nov 13, 2026, 2:27 AM EST
Terminated Early Phase 1 Interventional

Brain Imaging in the Diabetes Prevention Program Outcomes Study

NCT03757910
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-MK-6240, 11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 2 Interventional Results available

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05287113
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years to 99 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 2 Interventional Results available

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

NCT02477020
View directory record Official record
Conditions
Schizophrenia
Interventions
TAK-063 20 mg, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Springdale, Alaska • Culver City, California • Lemon Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

NCT01910220
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN1033 (SAR391786), placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Gainesville, Florida • Orlando, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Nov 13, 2026, 2:27 AM EST
Withdrawn Phase 2Phase 3 Interventional

Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD

NCT03674320
View directory record Official record
Conditions
COPD
Interventions
Testosterone Enanthate, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 1 Interventional

A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis

NCT01016223
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Beclomethasone dipropionate, placebo
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2012 · Synced Nov 13, 2026, 2:27 AM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480
View directory record Official record
Conditions
SLE
Interventions
Envudeucitinib, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
48
States / cities
Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 13, 2026, 2:27 AM EST
Not listed Phase 2 Interventional

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

NCT04869579
View directory record Official record
Conditions
Covid19
Interventions
Selenium (as Selenious Acid), Placebo
Drug · Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Longview, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

NCT04146363
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
30
States / cities
Fort Smith, Arkansas • Beverly Hills, California • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 3 Interventional

SLV308 for Treatment of Patients With Early Parkinson's Disease

NCT00269516
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2008 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of AG-348 in Healthy Volunteers

NCT02108106
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AG-348, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of SRP-4053 in DMD Patients

NCT02310906
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Placebo, SRP-4053
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
6 Years to 15 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Nov 13, 2026, 2:27 AM EST
Completed Not applicable Interventional

Effects of Cranberry Juice on Cardiovascular Risk Factors

NCT02556749
View directory record Official record
Conditions
Cardiovascular Disease Risk Factors
Interventions
Cranberry Juice Beverage, Placebo Beverage
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
94
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Nov 13, 2026, 2:27 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Characterization of Wild Blueberry Polyphenols Bioavailability and Kinetic Profile Over 24-hour Period

NCT02167555
View directory record Official record
Conditions
Overweight, Obese, Healthy
Interventions
Active Comparator, Placebo Comparator
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 2 Interventional

Dose Finding Study for QAW039 in Asthma

NCT01437735
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Montelukast, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Scottsdale, Arizona • Encinitas, California • Huntington Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Nov 13, 2026, 2:27 AM EST
Completed Phase 1 Interventional

Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus

NCT00233935
View directory record Official record
Conditions
Barrett Esophagus
Interventions
placebo, defined green tea catechin extract
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Nov 13, 2026, 2:27 AM EST
Terminated Phase 3 Interventional Results available

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

NCT03285308
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
Placebo, Relamorelin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
113
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Nov 13, 2026, 2:27 AM EST
Completed Not applicable Interventional Results available

Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease

NCT00379808
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
montelukast, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Nov 13, 2026, 2:27 AM EST